News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeClinical Forum InsightsMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2025|
AES 2025|
NSGC 2025
Advertisement

Suraj Muley, MD, Director of Neurology at the Bob Bove Neuroscience Institute at Honor Health, Professor of Medicine at ASU School of Medicine

Advertisement

Articles by Suraj Muley, MD, Director of Neurology at the Bob Bove Neuroscience Institute at Honor Health, Professor of Medicine at ASU School of Medicine

Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)

BySuraj Muley, MD, Director of Neurology at the Bob Bove Neuroscience Institute at Honor Health, Professor of Medicine at ASU School of Medicine
October 28th 2025
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

    1

    Overviewing Emerging Evidence of Vaccines, Dementia Risk, and Pathogen Protection: Pierre Tariot, MD

    2

    What the EC Decision on High-Dose Spinraza Means for SMA Care

    3

    Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time

    4

    Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits

    5

    Advancing Alzheimer Diagnosis and Treatment Through Mechanism-Based Approaches: Takeshi Iwatsubo, MD, PhD

    • About Us
    • Advisory Board
    • Editorial
    • Contact Us
    • Advertise
    • Contact MJH LS
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Contagion Live
    • CGT Live
    • Neurology Live
    • HCP Live
    • Oncology Live
    • Contemporary Pediatrics
    • Contemporary OBGYN
    • Urology Times
    • The Educated Patient
    HCP Live
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us